Phlegmatic Kala eyes ophthalmics with $11.5m Series A
This article was originally published in Scrip
Executive Summary
Kala Pharmaceuticals raised $11.5 million in a Series A venture funding round to support a new focus on ophthalmic diseases with the Waltham, Massachusetts-based company's Mucosal-Penetrating Products (MPP) platform. Phlegm